Bio Saga Blog - A Chronicle of Life Sciences & Informatics

Opportunity for Freshers as Medical Editor post at Cactus Communications, Mumbai Cactus Communications is a pioneering language services company serving more than 25,000 clients across 73 countries. In line with its mission—growth through effective communication, Cactus offers specialist academic editing, medical communications, publication support, transcription, and training services to individuals and corporations across sectors such as academia, publishing, and pharmaceuticals.  Candidates with scientific field degree apply for Specialist – CSD Job at Novartis A global healthcare leader, Novartis has one of the most exciting product pipelines in the industry today. A pipeline of innovative medicines brought to life by diverse, talented and performance driven people. All of which makes us one of the most rewarding employers in our field. Designation : Specialist – CSD Job Description Freshers jobs at Jubilant LifeSciences – Biotech/ Biochem/ Microbiology Jubilant Biosys Ltd, ...

Shares of Gen-Probe jumped 14 percent today after  Bloomberg  reported that the firm has hired Morgan Stanley to seek a buyer. Among the possible bidders listed in the article are Novartis, Thermo-Fisher Scientific, Danaher, and Life Technologies. Novartis already sells Gen-Probe's Tigris blood-screening instrument to blood banks, and it has  helped fund development  of Gen-Probe's new automated molecular testing platform, called Panther. The firms have collaborated since 1998 on nucleic acid tests and instruments for the blood screening market. According to Mizuho analyst Peter Lawson, around $12 billion has been spent on diagnostics-focused merger and acquisition activity over the past year. He noted that typical molecular and proprietary-focused acquisition valuations fall into the 3x-6x price/sales range. Two months ago, Gen-Probe  reported full-year 2010 revenues  of $543.3 million. At that time, it also reported a 2 percent decrease in fourt...

Industry response to the H1N1 pandemic suggests that cell culture vaccine production is about to come of age with two firms that use the technique, Novartis and Baxter, claiming it will cut development and manufacturing timelines by months. Margaret Chan officially declared the pandemic explaining that H1N1 infections worldwide can no longer be traced and that “ further spread is considered inevitable .” She asked drugmakers to begin preparing for large-scale H1N1 vaccine production when manufacture of seasonal stocks is completed, prompting a flurry of industry updates from vaccine producers. Baxter and Novartis aim for early availability The most eye-catching of these responses came from US drugmaker Baxter which announced it has completed testing of its Celvapan H1N1 vaccine and is “ now in full-scale production ,” and is working to deliver it as early as next month. Traditionally, seasonal influenza vaccines are mass produced using the albumin found in fertilised hens eggs a...